With the acquisition of Crelux, the global pharmaceutical group WuXi AppTec is strengthening its capabilities in structure-based drug discovery and establishing a research location in Europe for the first time.
A good day for the Innovation and Start-up Center for Biotechnology (IZB): WuXi AppTec, a leading global research and development service company in the pharmaceutical, biotech and medical device industries, is taking over the Crelux GmbH and thus also chooses Martinsried as a European location.
WuXi AppTec is thus bringing one of the leading companies in structure-based drug discovery on board. The integration of Crelux will deepen the Chinese pharmaceutical group's technical and scientific capabilities and complement the existing capabilities of WuXi AppTec's structure-based drug discovery platform.
Crelux GmbH was founded in 2005. As a global leader in structure-based drug discovery, Crelux has been providing research companies with customized and efficient solutions to accelerate their programs for over ten years. In particular, this includes services to support early-stage drug discovery, such as hit discovery and hit-to-lead optimization, and includes the following services: protein production, biophysical drug interaction studies, fragment-based screening, and X-ray crystallography.
The acquisition of CRELUX represents a significant contribution to WuXi AppTec's growing presence in Europe and confirms its clear commitment to serving European customers even better. For existing and new customers of both companies, the acquisition will result in more efficient access and improved service in the areas of hit-finding, hit-to-lead, and lead optimization, explains Dr. Steve Yang, Executive Vice President and Chief Operating Officer of WuXi AppTec.
"It has always been a key strategic goal for Crelux to integrate its expertise and technologies into the most comprehensive research and development services possible. Therefore, the combination with WuXi App Tec is a perfect deal for us. Our merger will benefit the European and global drug discovery and development industry at the highest level."
said Dr. Michael Schaeffer, Co-founder, Business and Strategy Executive Director of Crelux.
